Search

Your search keyword '"MCARTHUR, GRANT A."' showing total 66 results

Search Constraints

Start Over You searched for: Author "MCARTHUR, GRANT A." Remove constraint Author: "MCARTHUR, GRANT A." Publisher elsevier bv Remove constraint Publisher: elsevier bv
66 results on '"MCARTHUR, GRANT A."'

Search Results

1. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

3. A tailored approach to horizon scanning for cancer medicines

4. A tailored approach to horizon scanning for cancer medicines

5. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

6. Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA

7. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

8. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

9. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

13. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

14. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

15. A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response

16. Molecular Genomic Profiling of Melanocytic Nevi

17. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

18. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib

19. Adverse events 2.0—Let us get SERIOs

20. Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel

21. Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

23. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

24. Oncogenic Signaling Pathways in The Cancer Genome Atlas

25. Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

26. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

27. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

28. Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

29. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

32. Survival of patients with advanced metastatic melanoma: The impact of novel therapies

33. Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

34. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib

37. Expanded access programmes: patient interests versus clinical trial integrity

38. The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells

40. Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

42. The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound

44. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

45. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

48. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors

49. 92

50. Frequency of Fibroblast Growth Factor Receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome

Catalog

Books, media, physical & digital resources